Fraud and retraction in perioperative medicine publications: what we learned and what can be implemented to prevent future recurrence

被引:12
|
作者
Nato, Consolato Gianluca [1 ]
Tabacco, Leonardo [1 ]
Bilotta, Federico [1 ]
机构
[1] Umberto Policlin Roma, Dept Anaesthesiol Crit Care & Pain Med, I-00161 Rome, Italy
关键词
applied and professional ethics; anaesthetics; anesthesiology; clinical ethics; education; ethics; RANDOMIZED CONTROLLED-TRIALS; SURGICAL SITE INFECTION; FUJII ET-AL; POSTOPERATIVE NAUSEA; ARTICLE; SEE; HYDROXYETHYL STARCH; SUPPLEMENTAL OXYGEN; NONCARDIAC SURGERY; 30-35-PERCENT FRACTION; ANASTOMOTIC DEHISCENCE;
D O I
10.1136/medethics-2021-107252
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
Fraud in medical publications is an increasing concern. In particular, disciplines related to perioperative medicine-including anaesthesia and critical care-currently hold the highest rankings in terms of retracted papers for research misconduct. The dominance of this dubious achievement is attributable to a limited number of researchers who have repeatedly committed scientific fraud. In the last three decades, six researchers have authored 421 of the 475 papers retracted in perioperative medicine. This narrative review reports on six cases of fabricated publication in perioperative medicine that resulted in the paper's retraction. The process that led to the unveiling of the fraud, the impact on clinical practice, and changes in regulatory mechanisms of scientific companies and governmental agencies' policies are also presented. Fraud in medical publications is a growing concern that affects perioperative medicine requiring a substantial number of papers to be retracted. The continuous control elicited by readers, by local institutional review boards, scientific journal reviewers, scientific societies and government agencies can play an important role in preserving the 'pact of trust' between authors, professionals and ultimately the relationship between doctors and patients.
引用
收藏
页码:479 / 484
页数:6
相关论文
共 50 条
  • [21] After counterfeit Avastin®—what have we learned and what can be done?
    Tim K. Mackey
    Raphael Cuomo
    Camille Guerra
    Bryan A. Liang
    Nature Reviews Clinical Oncology, 2015, 12 : 302 - 308
  • [22] After counterfeit Avastin®-what have we learned and what can be done?
    Mackey, Tim K.
    Cuomo, Raphael
    Guerra, Camille
    Liang, Bryan A.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (05) : 302 - 308
  • [23] A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
    Liu, Christine
    Kieltyka, Jacqueline
    Fleischmann, Roy
    Gadina, Massimo
    O'Shea, John J.
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (12) : 2166 - 2178
  • [24] Stable vices: What are they, and can we prevent them?
    Waran, NK
    Henderson, J
    EQUINE PRACTICE, 1998, 20 (05): : 6 - 8
  • [25] What's new in ARDS: can we prevent it?
    Brower, Roy G.
    Antonelli, Massimo
    INTENSIVE CARE MEDICINE, 2016, 42 (05) : 772 - 774
  • [26] What can we do to prevent listeriosis in 2006?
    Goulet, Veronique
    CLINICAL INFECTIOUS DISEASES, 2007, 44 (04) : 529 - 530
  • [27] What urothelial recurrences can we prevent or treat?
    Xylinas, E.
    Bessede, T.
    PROGRES EN UROLOGIE, 2012, 22 : 6 - 10
  • [28] What’s new in ARDS: can we prevent it?
    Roy G. Brower
    Massimo Antonelli
    Intensive Care Medicine, 2016, 42 : 772 - 774
  • [29] WHAT CAN WE DO TO PREVENT HEART DISEASE
    不详
    JOURNAL OF THE AMERICAN COLLEGE HEALTH ASSOCIATION, 1973, 22 (02): : 73 - 74
  • [30] Subaortic stenosis and recurrence: what we can influence and what nature decides
    Dodge-Khatami, Ali
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023, 64 (04)